A long-term study of flurbiprofen in rheumatological disorders: II. Osteoarthrosis.
Two hundred and twenty-one patients with osteoarthrosis were evaluated over 18 months in the course of an open, multicentre study in the United Kingdom of the efficacy and safety of the non-steroidal anti-inflammatory drug (NSAID) flurbiprofen (Froben), in which a total of 1,396 patients with a variety of rheumatological disorders took part. Highly significant (p less than 0.001) improvements in pain sources were reported during the first 6 months of treatment, remaining significant for the rest of the 18 months of the study, and a global evaluation of progress made by doctor and patient recorded highly significant improvements by both. Improvement was particularly marked in those who had failed to respond to a previously administered drug, and in the elderly. Side-effects occurred in 21% of those not receiving other NSAIDs concomitantly, and were higher in women than in men who took other drugs at the same time. Side-effects were similar in nature to those of other drugs in this group and no correlation in their frequency or severity with the dosage of flurbiprofen was found.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D011422:Propionates / Q000627:therapeutic use*; D006113:United Kingdom
D011422:Propionates; D005480:Flurbiprofen